Plasma oxylipin profiling identifies polyunsaturated vicinal diols as responsive to arachidonic acid and docosahexaenoic acid intake in growing piglets

Maaike J. Bruins,† Adrie D. Dane,† Katrin Strassburg,† Rob J. Vreeken,† John W. Newman,§ Norman Salem, Jr.,**, Cynthia Tyburczy,†† and J. Thomas Brenna††

DSM Biotechnology Center,† Delft, The Netherlands; Netherlands Metabolomics Centre (NMC),† Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University, Leiden, The Netherlands; Obesity and Metabolism Research Unit,§ US Department of Agriculture (USDA), Agricultural Research Service (ARS), Western Human Nutrition Research Center, Davis, CA; DSM Nutritional Lipids,**, Columbia, MD; and Division of Nutritional Sciences,†† Cornell University, Ithaca, NY

Abstract The dose-responsiveness of plasma oxylipins to incremental dietary intake of arachidonic acid (20:4n-6; ARA) and docosahexaenoic acid (22:6n-3; DHA) was determined in piglets. Piglets randomly received one of six formulas (n = 8 per group) from days 3 to 27 postnatally. Diets contained incremental ARA or incremental DHA levels as follows (% fatty acid, ARA/DHA): (A1) 0.1/1.0; (A2) 0.53/1.0; (A3–D3) 0.69/1.0; (A4) 1.1/1.0; (D1) 0.66/0.33; and (D2) 0.67/0.62, resulting in incremental intake (g/kg BW/day) of ARA: 0.07 ± 0.01, 0.43 ± 0.03, 0.55 ± 0.03, and 0.82 ± 0.05 at constant DHA intake (0.82 ± 0.05), or incremental intake of DHA: 0.27 ± 0.02, 0.49 ± 0.03, and 0.81 ± 0.05 at constant ARA intake (0.54 ± 0.04). Plasma oxylipin concentrations and free plasma PUFA levels were determined at day 28 using LC-MS/MS. Incremental dietary intake dose-dependently increased plasma ARA levels. In parallel, ARA intake dose-dependently increased ARA-derived diols 5,6- and 14,15-dihydroxyicosatrienoic acid (DiHETE) and linoleic acid-derived 12,13-dihydroxyoctadecenoic acid (DiHOME), downstream metabolites of cytochrome P450 epoxycycloxa(n)-nase (CYP). The ARA epoxide products from CYP are important in vascular homeostatic maintenance. Incremental DHA intake increased plasma DHA and most markedly raised the eicosapentaenoic acid (EPA) metabolite 17,18-di-hydroxyeicosatetraenoic acid (DiHETE) and the DHA metabolite 19,20-dihydroxycosapentaenoic acid (DiHDPE). In conclusion, increasing ARA and DHA intake dose-dependently influenced endogenous n-6 and n-3 oxylipin plasma concentrations in growing piglets, although the biological relevance of these findings remains to be determined.—Bruins, M. J., A. D. Dane, K. Strassburg, R. J. Vreeken, J. W. Newman, N. Salem, Jr., C. Tyburczy, and J. T. Brenna. Plasma oxylipin profiling identifies polyunsaturated vicinal diols as responsive to arachidonic acid and docosahexaenoic acid intake in growing piglets. J. Lipid Res. 2013. 54: 1598–1607.

Supplementary key words lipidomics • metabolomics • eicosanoid • prostaglandin • omega-3 • omega-6 polyunsaturated fatty acid

Human milk contains the essential fatty acids linoleic acid (18:2n-6) and α-linolenic acid (18:3n-3) and their respective n-3 and n-6 long-chain polyunsaturated fatty acid (LCPUFA) metabolites. Arachidonic acid (20:4n-6; ARA) and docosahexaenoic acid (22:6n-3; DHA) are the most abundant LCPUFA in human milk (1). DHA and ARA accumulate in brain and retina at a high rate during the last trimester of pregnancy and the first months of life (2). DHA and ARA may be synthesized in the body from the precursor essential fatty acids, α-linolenic acid (18:3n-3; ALA) and linoleic acid (18:2n-6; LA), respectively. However, the endogenous conversion efficiency of these precursor fatty

Abbreviations: ALA, α-linolenic acid; ARA, arachidonic acid; BW, body weight; COX, cyclooxygenase; CYP, cytochrome P450 epoxycycloxa(n)-nase; DGLA, dihomo-γ-linolenic acid; DHA docosahexaenoic acid; EPA, eicosapentaenoic acid; DihDPE, dihydroxyicosapentaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHDPE, dihydroxydocosapentaenoic acid; EpDPE, epoxydocosapentaenoic acid; EpETE, epoxycosatrienoic acid; EpOME, epoxyoctadecamonoenoic acid; FDR, false discovery rate; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HHTE, hydroxyheptadecatrienoic acid; HODE, hydroxyoctadecadienoic acid; HOTIE, hydroxyoctatrienoic acid; KODE, ketoctadecadienoic acid; LA, linoleic acid; LOX, lipoygenase; PG, prostaglandin; LCPUFA, long-chain polyunsaturated fatty acid; sEH, soluble epoxide hydrolase; TX, thromboxane.

1Present address of C. Tyburczy: Center for Food Safety and Applied Nutrition, Office of Regulatory Science, US Food and Drug Administration, College Park, MD.

2To whom correspondence should be addressed. e-mail: jtb4@cornell.edu

The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of one figure and three tables.
acids to ARA and DHA is estimated to be low in infants and not as efficient as preformed ARA and DHA in sustaining ARA and DHA plasma levels (3–6). Many studies indicate that DHA and ARA-enriched formula from birth to one year of age may confer benefits on visual acuity maturation and aspects of cognitive development compared with unenriched formula, particularly in premature infants (7–12).

Fatty acids of the n-3 and n-6 families are dose-dependently incorporated into cell membranes (13, 14). Data from animal studies have demonstrated that during early growth and development, the brain is particularly sensitive to DHA intake (15), while thymus (16), small intestine (17), liver, and heart (18) are particularly sensitive to ARA intake. Nonesterified PUFA can be enzymatically oxidized to generate a wide range of lipophilic signaling molecules known collectively as oxylipins (19). The polyunsaturated fatty acids linoleic acid, dihomo-γ-linolenic acid (20:3n-6; DGLA), ARA, α-linolenic acid, eicosapentaenoic acid (20:5n-3; EPA), and DHA are the main precursors for various oxylipins (19). The three primary enzymes catalyzing the oxygenation of these fatty acids into oxylipins are the cytochrome P450 exoxygenases (CYP), cyclooxygenases (COX), and lipoxygenases (LOX) (19). Other enzymes, such as soluble epoxide hydrolases (sEH), can further metabolize some of the oxylipin species.

Oxylipins are currently the focus of considerable interest as they can act as intercellular signaling molecules and are involved in the regulation of many cell and tissue responses (20). Oxylipins can exert a wide range of effects in biological tissues, including the regulation of cellular proliferation (21, 22), inflammation or inflammation resolution (23–25), and vascular function (23, 26). Novel analytical methodologies to quantify the large spectrum of plasma lipids have emerged and reveal a remarkable diversity of oxylipins in human plasma (19, 27). The biological roles of many of these oxylipins have not yet been fully elucidated. Over the past decade there has been growing interest in pharmacological modulation of oxylipin enzymatic pathways to mediate beneficial vascular and inflammatory effects (28–32).

Oxylipins are currently the focus of considerable interest as they can act as intercellular signaling molecules and are involved in the regulation of many cell and tissue responses (20). Oxylipins can exert a wide range of effects in biological tissues, including the regulation of cellular proliferation (21, 22), inflammation or inflammation resolution (23–25), and vascular function (23, 26). Novel analytical methodologies to quantify the large spectrum of plasma lipids have emerged and reveal a remarkable diversity of oxylipins in human plasma (19, 27). The biological roles of many of these oxylipins have not yet been fully elucidated. Over the past decade there has been growing interest in pharmacological modulation of oxylipin enzymatic pathways to mediate beneficial vascular and inflammatory effects (28–32).

In previous studies with mice (30) and healthy volunteers (19, 31), it was shown that dietary intake of n-3 LCPUFA was able to alter plasma oxylipin levels. Despite intense interest in the biological effects of dietary LCPUFA in infant nutrition, the influence of dietary DHA and ARA on plasma oxylipin levels has not previously been explored in growing mammals, including humans. We report here a lipodomics-based study of plasma oxylipin profile using a dose-response design in growing piglets.

**MATERIALS AND METHODS**

**Animals**

The study was conducted in conformity with the Public Health Service Policy on Humane Care and approved by the Institutional Animal Care and Use Committee at Cornell University. Details of the experimental methods have been described elsewhere (18). Briefly, piglets aged three days postnatal, were randomly assigned to receive one of six formula diets or to continue maternal rearing (n = 8 per group; 4 males and 4 females). Piglet weights at day three varied between 1.70 and 2.45 kg. Piglets from the different litters (2–3 piglets per litter) and of different weights were uniformly distributed among the groups. Formula diets were fed from age 3 to 27 days. Total 24 h formula intake was measured daily in the morning. Formula diets consisted of 60% experimental diet (Research Diets, Inc., New Brunswick, NJ) and 40% Birthright baby pig milk replacer (Ralco Nutrition, Inc., Marshall, MN). The composition of the formula diets has been previously reported (18). Formula diets had a caloric density of 0.7 kcal/ml. Diets contained constant DHA concentrations (1.02 ± 0.02 wt% of total fatty acids) in conjunction with increasing ARA concentrations [0.09 (A1), 0.53 (A2), 0.69 (A3–D3)], and 1.06 (A4) wt% of total fatty acids, respectively] or constant ARA concentrations (0.67 ± 0.02 wt% of total fatty acids) with incremental DHA concentrations [0.33 (D1), 0.62 (D2), 1.04 (A3–D3) wt% of total fatty acids, respectively]. The dietary ARA levels (0.67 wt%) are reflective of current human infant formulas. The DHA levels (1.02 wt%) are higher than in infant formula (0.35 wt%), reflecting high-end breast milk concentrations of fish-eating populations (1).

Venous blood was collected at day 28, the morning after last formula feeding at day 27. Details have been described elsewhere (18). Plasma levels of free fatty acids were analyzed by LC-MS/MS. In short, protein in the samples was precipitated by adding 50 µl of internal standard solution and 1050 µl of methanol to 50 µl of plasma. After centrifugation, the supernatant was transferred into an injection vial. For relative quantification, a mixture of internal standards [32 exogenous calibrants and 12 internal standards] was used. The free fatty acids were analyzed by LC-MS/MS using a Waters ACQUITY UltraPerformance LC (UPLC) System with an ACQUITY UPLC HSS T3 1.8 µm, 2.1 × 100 mm column (Waters, Milford, MA) and an Agilent Q-TOF 6500 High Resolution Mass Spectrometer (Agilent, Santa Clara, CA) using reference mass correction. Data preprocessing was performed using Agilent MassHunter Quantitative Analysis software; all peaks were checked with a Waters AQCUITY UltraPerformance LC (Agilent 1260, San Jose, CA) using an Ascentis Express column (2.1 × 150 mm, 2.7 µm particles; Supelco, Bellefonte, PA) with 0.35 mL/min flow rate during a 28 min gradient. The HPLC was coupled to electrospray ionization on a triple-quadrupole mass spectrometer (Agilent 6460, Santa Jose, CA). Oxylipins were detected in negative ion mode using dynamic multiple reaction monitoring (MRM). The raw data were preprocessed using Agilent MassHunter Quantitative Analysis software (Version B.04.00), and quantitation of oxylipin response was calculated as the peak area ratios of the target analyte to the respective internal standard. To obtain actual concentrations, calibration samples with spiked oxylipin levels were included in the measurement series. Oxylipins were classified according to the LIPID MAPS Structure Database (33).
RESULTS

Effect of ARA on plasma PUFA levels

Dietary intervention groups receiving incremental dietary ARA levels, consumed on average 0.07 ± 0.01, 0.43 ± 0.03, 0.55 ± 0.03, and 0.82 ± 0.05 g of ARA/kg BW/day, respectively, at constant DHA (0.82 ± 0.05g/kg BW/day) over the course of 24 days of formula feeding (Table 1). Mixed model regression analysis showed that incremental ARA intake by the piglets significantly increased the plasma levels of ARA (Table 1). The significant increase in plasma DHA, linoleic acid, and α-linolenic acid levels that occurred with increasing ARA intake disappeared after correcting for multiple testing (Table 1). Supplementary Table I shows the coefficients, P values, and FDRs obtained from linear mixed modeling for the relationships between ARA intake and plasma fatty acid levels.

Effect of DHA on plasma PUFA levels

The three dietary DHA levels resulted in a mean DHA intake of 0.27 ± 0.02, 0.49 ± 0.03, and 0.81 ± 0.05 g/kg BW/day, respectively, at constant ARA intake (0.54 ± 0.04 g/kg BW/day) over the 24 days of feeding. The plasma levels of DHA dose-dependently increased with higher amounts of DHA ingested (Table 1). Other plasma fatty acids were not significantly affected. Dietary DHA in our study did not significantly affect plasma EPA levels, but heart and liver tissue phospholipid EPA levels increased with DHA (data not shown). The coefficients, P values, and FDRs for the effects of dietary DHA intake on plasma fatty acids are shown in supplementary Table I.

Detected plasma oxylipins

The metabolites, identified in pig plasma after 24 days of dietary intake, are shown in Tables 2 and 3. Supplementary Fig. 1 shows MS/MS spectra, MRM transition information, and structures of diols detected in piglet plasma. Despite sufficient sensitivity of the method, only oxylipins known to be enzymatically produced were detected (i.e., no nonenzymatically produced metabolites were detected). Linoleic acid-derived metabolites included 9- and 13-hydroxyoctadecadienoic acid (HODE), 15-ketooctadecadienoic acid (KODE), 9(10)- and 12(13)-epoxyoctadecenoic acid (EpOME), and 9,10- and 12,13-dihydroxyoctadecenoic acid (DiHOME). The prostaglandin F2α (PGF2α) metabolite detected in plasma is a dihomo-γ-linolenic acid-derivived oxylipin. Detected ARA metabolites included prostaglandin-E2 (PGF2), prostaglandin F2α (PGF2α), 13, 14-dihydro-15-keto-PGF2α, thromboxane (TXB2), 12S-hydroxy-heptadecatrienoic acid (HHTrE), 5-, 8-, 11-, 12-, and 15-hydroxyeicosatetraenoic acid (HETE), and 5,6-, 11,12-, and 14,15-dihydroxyicosatetraenoic acid (DiHETE). 19-Hydroxyeicosaatetraenoic acid (HOTrE) is derived from α-linolenic acid. Derivatives of EPA comprised prostaglandin-F2α, 5S-hydroxyeicosapentaenoic acid (HEPE), and 17,18-dihydroxyeicosatetraenoic acid (DiHETE). Oxylipins from DHA included 19(20)-epoxydocosapentaenoic acid (EpDPE) and 19,20-dihydroxydocosapentaenoic acid (DiHDPE). The DHA-derivatives 16,17-EpDPE and 5(6)- and 14(15)-epoxyicosatrienoic acid (EpETrE) were below the detection limits. Plasma oxylipin concentrations were in a similar range as measured previously in humans (19) except for a few metabolites [e.g., 19(20)-EpDPE and 5-HETE], which were exceptionally high in one or two piglets, causing high mean values and standard deviations. Because we had no independent indication that the corresponding measurements were outliers, they were not removed but attributed to biological variation.

Effect of ARA intake on plasma oxylipins

Regression analysis demonstrated that incremental ARA intake significantly increased plasma concentrations of the CYP/sEH-derived ARA metabolites 5,6-DiHETrE and 14,15-DiHETE after correcting for multiple testing (Table 2 and Fig. 1A, B). The coefficients, P values, and FDRs of the mixed modeling are shown in supplementary Table II. Incremental ARA intake by the piglets did not significantly affect any of the detected ARA-derived LOX- or COX-synthesized eicosanoids (3-HETE, 8-HETE, 11-HETE, 12-HETE, 15-HETE, TXB2, PGF2α, PGE2, and 13,14-dihydro-15-keto-PGF2α).

Increasing ARA intake elevated plasma 12,13-DiHOME, a CYP/sEH-derived metabolite of linoleic acid (Fig. 1C and Table 2). No significant effects of ARA intake were observed on DHA, α-linolenic acid, or dihomo-γ-linolenic acid derivatives following multiple comparison correction.

Effect of DHA intake on plasma oxylipins

DHA intake dose-dependently increased the plasma CYP/sEH-catalyzed DHA metabolite 19,20-DiHDPE after the multiple comparison procedure (Table 3 and Fig. 2A), although no effect of DHA was apparent on the precursor metabolite 19(20)-EpDPE. Dietary DHA also increased the CYP/sEH-catalyzed EPA metabolite 17,18-DiHETE (Fig. 2B), but the precursor 17(18)-EpEETE was not detected in

Statistics

All statistical analyses were performed using R version 2.13.0. Relative response ratios of oxylipins were converted into actual concentrations (nM) using the R chemCal package (free software, R-project). Second-order (quadratic) regression models were applied to examine dose-response relationships between the 24 day mean dietary DHA or ARA intake and log plasma oxylipin or log PUFA levels. As predictor, variable dietary levels were corrected for effective intake per body weight (BW) throughout growth by expressing as g/kg BW/day. Linear mixed modeling was performed for varying dietary DHA intake (at fixed ARA intake), for gender, and their interactions as independent (fixed) variable, and litter as a random variable. To remove nonsignificant terms, stepwise regression was used. Some dose-response curves followed a curvilinear (quadratic) relationship. Therefore, we also included a quadratic term in our stepwise regression approach. Modeling for varying ARA intake was performed in the same way but with DHA intake as the fixed factor. The maternally reared group was excluded from the analysis as the sow’s diet differed from the formula diets in more aspects than only DHA and ARA concentrations. The LC-MS/MS data were log-transformed before modeling. False discovery rate (FDR) control was used to correct for multiple comparisons. Data are presented as the mean ± SD.
plasma. No significant effects were observed of increasing DHA intake on oxylipins derived from α-linolenic acid, ARA, DGLA, or linoleic acid after correcting for multiple comparisons. The coefficients, P values, and FDRs are shown in supplementary Table III.

**DISCUSSION**

Pigs are an accepted model of human nutrition since they are very similar to humans with respect to anatomy, physiology (34, 35), and fatty acid metabolism (36). Based on the high homology between the pig and human genome, high sequence homology between human and porcine COX and LOX enzymes can be expected. Some porcine CYP enzymes showed about 70–83% homology to human forms and metabolized the same test substrates (37). This is the first study to report on the dose responsiveness of fatty acid-derived oxylipins to dietary intake of ARA and DHA during early postnatal development in piglets. The use of metabolomics technology in this study allowed us to characterize the detectable piglet oxylipin metabolo
e. The data show that some endogenous n-6 and n-3 oxylipin levels can be dose-dependently modulated by dietary DHA and ARA levels. Most oxylipin curves did not follow Michaelis-Menten enzyme kinetics, which could be explained by the involvement of multiple downstream enzymes in their production and the nonclassical enzyme kinetics as described for some CYP enzymes (38). The extent to which these oxylipins may mediate beneficial health effects remains to be explored. These data help to focus such studies on particular oxylipin species in various dietary circumstances of ARA/DHA intake during early development.

**Arachidonic acid metabolites**

Eicosanoids generated via COX and LOX exert many important functions, as exemplified by various pathologies manifested in mice lacking LOX and COX expression (39, 40). Despite the traditional belief that ARA-derived eicosanoids generated via the COX or LOX pathway contribute to the initiation of inflammation, emerging data suggest that these eicosanoids also contribute to the resolution of inflammation (23, 41–44). In perinatal development, COX-catalyzed PGE2 is an important lipid metabolite not only in immune cell homeostasis (45) but also in intestinal crypt proliferation (45) and preservation of neural function (46). Results of this study in growing piglets demonstrate that increasing dietary ARA levels do not affect plasma concentrations of the LOX- or COX-synthesized ARA metabolites, including PGE2, in spite of the increased levels of ARA in plasma and tissue (18). Also, plasma inflammation markers remained unchanged by increasing dietary ARA, as was previously reported (47). Although DHA may compete with ARA for membrane phospholipid incorporation and subsequent eicosanoid formation, dietary DHA also did not influence any of LOX- or COX-synthesized ARA metabolites. In several studies, dietary n-3 LCPUFA was shown to reduce plasma levels of ARA metabolites. This suggests that the balance between ARA and DHA in the diet may affect the production of ARA-derived eicosanoids, which may have implications for the prevention and treatment of inflammatory diseases. Further research is needed to clarify the role of dietary DHA and ARA in the resolution of inflammation.
TABLE 2. Mean plasma concentrations (nM ± SD) of metabolites after increasing intake of ARA at constant DHA intake

| Metabolite | Lipid Map ID | Biosynthetic Pathway | PUFA | Mean ARA Intake (g/kg BW/day) | Effect$^b$ | N | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD |
|------------|--------------|----------------------|------|-------------------------------|-----------|---|------|----|---|------|----|---|------|----|---|------|----|
| 9(10)-EpOME | LMFA02000037 | CYP 18:2n-6 (LA) | 8 | 2.0 0.9 8 2.0 | 1.3 8 1.9 0.5 8 2.6 1.8 | ++ | 9 | 0.07 | | 9 | 0.43 | | 9 | 0.55 | | 9 | 0.82 | |
| 9,10-DiHOME | LMFA01050350 | CYP 18:2n-6 (LA) | 8 | 7.0 2.0 8 7.1 | 1.8 8 7.6 2.2 8 9.7 4.3 | | | | | | | | | | | |
| 12(13)-EpOME | LMFA02000038 | CYP 18:2n-6 (LA) | 8 | 2.5 1.3 8 2.8 | 1.4 8 2.5 1.4 8 3.3 2.1 | | | | | | | | | | | |
| 12,13-DiHOME | LMFA01050351 | CYP 18:2n-6 (LA) | 8 | 6.9 2.0 8 8.0 | 2.0 8 8.4 2.3 8 10.3 3.6 | | | | | | | | | | | |
| 9HODE | LMFA01050278 | LOX 18:2n-6 (LA) | 8 | 27.1 7.6 8 32.7 | 13.0 8 30.3 7.3 8 38.5 25.1 | | | | | | | | | | | |
| 13HODE | LMFA01050349 | LOX 18:2n-6 (LA) | 8 | 51.0 15.4 8 66.8 | 26.5 8 60.4 20.0 8 72.1 38.0 | | | | | | | | | | | |
| 13-KODE | LMFA02000016 | LOX 18:2n-6 (LA) | 8 | 3.7 2.0 8 3.4 | 1.1 8 4.3 1.7 8 5.2 2.9 | | | | | | | | | | | |
| 9HOTe | LMFA02000024 | LOX 18:3n-3 (ALA) | 8 | 1.2 0.4 8 1.2 | 0.6 8 1.3 0.4 8 1.5 0.9 | | | | | | | | | | | |
| PGF1α | LMFA03010137 | COX 20:3n-6 (DGLA) | 8 | 2.2 0.5 8 2.0 | 0.7 8 1.9 0.6 8 1.7 0.6 | | | | | | | | | | | |
| PGF2α | LMFA03010002 | COX 20:4n-6 (ARA) | 8 | 3.5 1.5 8 17.3 | 23.5 8 2.8 0.6 8 5.6 6.7 | | | | | | | | | | | |
| PGE2 | LMFA03010005 | COX 20:4n-6 (ARA) | 8 | 0.8 0.2 8 1.7 | 1.7 8 0.9 0.3 8 0.9 0.4 | | | | | | | | | | | |
| 13,14-dihydro-15-keto-PGFα | LMFA0301027 | COX 20:4n-6 (ARA) | 6 | 1.4 0.3 7 1.3 | 0.5 7 1.1 0.3 8 1.8 1.5 | | | | | | | | | | | |
| TXB2 | LMFA03030002 | COX 20:4n-6 (ARA) | 8 | 4.7 2.6 8 23.7 | 32.0 8 2.5 0.8 8 8.3 9.6 | | | | | | | | | | | |
| 11-HETE | LMFA03060028 | COX 20:4n-6 (ARA) | 8 | 2.5 3.5 8 3.4 | 3.3 8 3.4 0.4 8 2.2 0.9 | | | | | | | | | | | |
| 5,6-DHETe | LMFA03050004 | COX 20:4n-6 (ARA) | 8 | 1.2 0.5 8 1.5 | 0.4 8 1.8 1.0 8 2.3 0.7 | | | | | | | | | | | |
| 11,12-DiHETe | LMFA03050008 | COX 20:4n-6 (ARA) | 8 | 1.2 0.4 8 1.2 | 0.4 8 1.4 0.5 8 1.6 0.8 | | | | | | | | | | | |
| 14,15-DiHETe | LMFA03050101 | COX 20:4n-6 (ARA) | 8 | 2.4 0.6 8 3.8 | 0.9 8 3.5 0.8 8 4.3 1.0 | | | | | | | | | | | |
| 5HETE | LMFA03060002 | COX 20:4n-6 (ARA) | 8 | 38.5 74.6 8 32.0 | 37.5 8 17.4 8 16.3 7.1 | | | | | | | | | | | |
| 8HETE | LMFA03060006 | COX 20:4n-6 (ARA) | 8 | 3.7 3.2 8 3.4 | 2.2 8 2.7 0.8 8 3.5 1.1 | | | | | | | | | | | |
| 12-HETE | LMFA03060088 | COX 20:4n-6 (ARA) | 8 | 3.6 4.5 8 4.2 | 4.2 8 2.5 0.7 8 3.1 0.9 | | | | | | | | | | | |
| 15-HETE | LMFA03060001 | COX 20:4n-6 (ARA) | 8 | 2.5 2.3 8 4.1 | 3.4 8 1.8 0.5 8 2.1 0.7 | | | | | | | | | | | |
| PGF3α | LMFA03010138 | COX 20:5n-3 (EPA) | 8 | 6.4 3.4 8 8.9 | 7.8 7 7.8 5.0 8 6.0 3.0 | | | | | | | | | | | |
| 17,18-DiHETE | LMFA03060078 | COX 20:5n-3 (EPA) | 8 | 43.1 11.9 8 45.1 | 12.0 8 47.9 21.8 8 42.0 8.9 | | | | | | | | | | | |
| 5(S)-HEPE | LMFA03070010 | COX 20:5n-3 (EPA) | 8 | 2.3 3.4 8 2.0 | 2.4 8 1.0 0.4 8 0.8 0.4 | | | | | | | | | | | |
| 19(20)-EpiDPE | LMFA04000038 | COX 22:5n-3 (DHA) | 8 | 372.0 781.4 8 266.7 | 546.4 8 90.9 47.5 8 81.4 31.9 | | | | | | | | | | | |
| 19,20-DiHDPA | LMFA04000043 | COX 22:5n-3 (DHA) | 8 | 17.1 4.3 8 17.6 | 3.0 8 19.2 7.2 8 18.6 4.3 | | | | | | | | | | | |

$^a$ Lipid classification according to LIPID MAPS Structure Database (33).

$^b$ Significances by linear mixed modeling methodology for dose-response effect of dietary ARA or DHA and gender (interaction) effects on fatty acids. +/−, positive/negative term in the regression model; ++/−, significant at 95% confidence level; +/−, significant at 90% confidence level; (+), other terms; *, significant after FDR correction.
## TABLE 3. Mean plasma concentrations (nM ± SD) of metabolites after increasing intake of DHA at constant ARA

| Metabolite     | Lipid Map ID | Biosynthetic Pathway | PUFA      | Mean DHA intake (g/kg BW/day) | Effect |
|----------------|--------------|----------------------|-----------|-------------------------------|--------|
|                |              |                      |           | 0.27                         | 0.49   | 0.83 |
|                |              |                      |           | DHA                          | Gender | DHA Quadratic | DHA × Gender | DHA Quadratic × Gender |
| N             | Mean | SD | N     | Mean | SD | N     | Mean | SD | N     | Mean | SD | N     | Mean | SD |
| 9(10)-EpOME   | LMFA02000037| CYP | 18:2n-6 (LA) | 8 | 1.6 | 0.6 | 8 | 1.9 | 0.9 | 8 | 1.9 | 0.5 | (−) | − | (+) | + | − |
| 9,10-DiHOME   | LMFA01050350| CYP | 18:2n-6 (LA) | 8 | 7.6 | 1.6 | 8 | 6.7 | 1.6 | 8 | 7.6 | 2.2 | ++−−−− | ++ | − | ++ | + | − |
| 12(15)-EpOME  | LMFA02000038| CYP | 18:2n-6 (LA) | 8 | 2.6 | 1.0 | 8 | 2.7 | 1.0 | 8 | 2.5 | 1.4 | (−) | − | (+) | + | − |
| 12,13-DiHOME  | LMFA01050351| CYP | 18:2n-6 (LA) | 8 | 8.2 | 1.7 | 8 | 7.4 | 1.6 | 8 | 8.1 | 2.3 | −−−−−−−−−− | (+) | ++ | − |
| 9-HOIDE       | LMFA01050278| LOX | 18:2n-6 (LA) | 8 | 27.5 | 7.2 | 8 | 23.4 | 5.5 | 8 | 30.3 | 7.3 | − | −−−−−−−− | (+) | ++ | − |
| 13-HOIDE      | LMFA01050349| LOX | 18:2n-6 (LA) | 8 | 55.9 | 18.1 | 8 | 49.9 | 16.6 | 8 | 60.4 | 20.0 | (−) | −−−−−−−− | (+) | ++ | − |
| 15-KOIDE      | LMFA02000016| LOX | 18:2n-6 (LA) | 8 | 3.6 | 1.2 | 8 | 2.9 | 0.8 | 8 | 4.3 | 1.7 | − | −−−−−−−− | (+) | ++ | − |
| 9-HODE        | LMFA01050278| LOX | 18:2n-6 (LA) | 8 | 1.1 | 0.5 | 8 | 1.0 | 0.3 | 8 | 1.5 | 0.4 | − | −−−−−−−− | (+) | ++ | − |
| PGF1α         | LMFA03010137| COX | 20:3n-6 (DGLA) | 8 | 2.0 | 0.9 | 8 | 1.8 | 0.3 | 8 | 1.9 | 0.6 | − | −−−−−−−− | (+) | ++ | − |
| PGF2α         | LMFA03010002| COX | 20:4n-6 (ARA) | 8 | 3.5 | 1.4 | 8 | 4.3 | 2.8 | 8 | 2.8 | 0.6 | − | −−−−−−−− | (+) | ++ | − |
| PGE2          | LMFA03010003| COX | 20:4n-6 (ARA) | 8 | 0.9 | 0.6 | 8 | 0.9 | 0.9 | 8 | 0.9 | 0.3 | − | −−−−−−−− | (+) | ++ | − |
| 13,14-dihydro-15-keto-PGF2α | LMFA03010027| COX | 20:4n-6 (ARA) | 6 | 1.2 | 0.3 | 7 | 1.5 | 0.3 | 7 | 1.1 | 0.3 | (−) | − | (+) | − | (−) | (+) | ++ | − |
| TXB2          | LMFA03030002| COX | 20:4n-6 (ARA) | 8 | 3.1 | 1.1 | 8 | 5.5 | 3.9 | 8 | 2.5 | 0.8 | ++ | −−−−−−−− | (+) | ++ | − |
| 11-HETE       | LMFA03060028| COX | 20:4n-6 (ARA) | 8 | 1.8 | 0.7 | 8 | 2.3 | 1.8 | 8 | 1.5 | 0.4 | ++ | −−−−−−−− | (+) | ++ | − |
| 5,6-DiHETE    | LMFA03050004| COX | 20:4n-6 (ARA) | 8 | 1.8 | 0.5 | 8 | 2.0 | 1.2 | 8 | 1.8 | 1.0 | ++ | −−−−−−−− | (+) | ++ | − |
| 11,12-DiHETE  | LMFA03050008| CYP | 20:4n-6 (ARA) | 8 | 1.5 | 0.5 | 8 | 1.2 | 0.3 | 8 | 1.4 | 0.5 | ++ | −−−−−−−− | (+) | ++ | − |
| 14,15-DiHETE  | LMFA03050010| CYP | 20:4n-6 (ARA) | 8 | 3.9 | 1.4 | 8 | 3.4 | 1.1 | 8 | 3.5 | 0.8 | ++ | −−−−−−−− | (+) | ++ | − |
| 5-HETE        | LMFA03060002| CYP | 20:4n-6 (ARA) | 8 | 2.1 | 1.0 | 8 | 2.1 | 1.2 | 8 | 1.8 | 0.5 | ++ | −−−−−−−− | (+) | ++ | − |
| 8-HETE        | LMFA03060006| LOX | 20:4n-6 (ARA) | 8 | 22.0 | 24.6 | 8 | 29.0 | 46.1 | 8 | 17.4 | 8.9 | − | −−−−−−−− | (+) | ++ | − |
| 12-HETE       | LMFA03060088| LOX | 20:4n-6 (ARA) | 8 | 3.0 | 0.9 | 8 | 2.9 | 1.6 | 8 | 2.7 | 0.8 | − | −−−−−−−− | (+) | ++ | − |
| 13-HETE       | LMFA03060001| LOX | 20:4n-6 (ARA) | 8 | 3.2 | 2.1 | 8 | 3.3 | 3.4 | 8 | 2.5 | 0.7 | − | −−−−−−−− | (+) | ++ | − |
| PGF3α         | LMFA03010138| COX | 20:5n-3 (EPA) | 8 | 0.9 | 3.5 | 7 | 8.8 | 5.8 | 7 | 7.8 | 5.0 | −| −−−−−−−− | (+) | ++ | − |
| 17,18-DiHEPE  | LMFA03060078| CYP | 20:5n-3 (EPA) | 8 | 31.6 | 13.4 | 8 | 33.7 | 13.8 | 8 | 47.9 | 21.8 | − | −−−−−−−− | (+) | ++ | − |
| 5(S)-HEPE     | LMFA03070010| LOX | 20:5n-3 (EPA) | 8 | 0.6 | 0.2 | 8 | 1.0 | 0.9 | 8 | 1.0 | 0.4 | ++ | −−−−−−−− | (+) | ++ | − |
| 19(20)-EpdPHE| LMFA04000038| CYP | 22:5n-3 (DHA) | 8 | 84.4 | 13.8 | 8 | 116.7 | 197.9 | 8 | 90.9 | 47.5 | − | −−−−−−−− | (+) | ++ | − |
| 19,20-DiHDPA  | LMFA04000043| CYP | 22:5n-3 (DHA) | 8 | 11.7 | 4.1 | 8 | 12.9 | 4.2 | 8 | 19.2 | 7.2 | − | −−−−−−−− | (+) | ++ | − |

* Lipid classification according to LIPID MAPS Structure Database (33).

Significances by linear mixed modeling methodology for dose-response effect of dietary ARA or DHA and gender (interaction) effects on fatty acids. +/−, positive/negative term in the regression model; ++/−−−, significant at 95% confidence level; +/−−−, significant at 90% confidence level; (+)/(−), other terms; *, significant after FDR correction.
tissues may cause only a transient or nondetectable change in circulating concentrations due to dilution in the greater volume of blood.

Increasing ARA intake dose-dependently raised plasma ARA levels in parallel with plasma 5,6-DiHETrE and 14,15-DiHETrE concentrations. The dose-dependent increases in these vicinal diols suggest increased conversion of ARA via the CYP/sEH enzymatic pathway. The precursor epoxides 5(6)-EpETrE and 14(15)-EpETrE were however not detected. EpETrEs may be difficult to detect; most EpETrEs are esterified into phospholipids, whereas nonesterified EpETrEs are rapidly metabolized by sEH to their vicinal diols (26). In humans, 14(15)-EpETrE concentrations were on par with their corresponding vicinal diols (52). However, the analysis we employed had a one-third lower sensitivity for epoxides than for diols (27). Therefore,

ARA-derived LOX and COX products from ex vivo immune cells in the presence of an inflammatory stimulus (48–51). Our data provide no evidence that ARA-rich or DHA-rich formula influence circulating COX or LOX eicosanoids in healthy growing piglets. As physiologically comparable levels of ARA are found in human breast milk and infant formula, comparable effects in humans may be inferred. The LC-MS/MS method employed is sufficiently sensitive to detect multiple LOX- or COX-synthesized eicosanoids from ARA. The COX- and LOX-derived metabolites are rapidly inactivated and excreted, and some of these inactivation products are released to and/or created in the circulatory system. At continuous elevated production of eicosanoids, stable metabolites may accumulate to detectable levels in peripheral blood. However, a low-level production of mediators in peripheral

Fig. 1. Significant relationships between dietary ARA at constant DHA and (A) ARA-derived 5,6-DiHETrE, (B) ARA-derived 14,15-DiHETrE, and (C) linoleic acid-derived 12,13-DiHOME. Filled circle, male; open circle, female.
The epoxygenases of the CYP2 gene family have prominent roles in vascular regulation and generate the epoxides 5,6-, 8,9-, 11,12-, and 14,15-EpETE from ARA (53). EpETEs are produced by several tissues, including neural (54) and vascular tissues (55). Data from in vitro and in vivo studies demonstrate manifold biological activities of EpETEs, including anti-inflammatory, neuroprotective, and vascular-protective effects like vasodilation (reviewed in Refs. 56, 57). Little is known about CYP metabolism in pigs, but porcine ovary was found to highly express CYP2J and sEH and produce EpETEs and EpOMEs, as well as DiHETEs and DiHOMEs during ovulation (58). In cultured endothelial cells of porcine origin, generation of 8,9-, 11,12-, and 14,15-EpETE has also been observed (59, 60). In growing pigs, EpETEs may play an important role in vascular formation, as they were shown to be involved in proliferation of porcine endothelial cells (61). These EpETEs are further metabolized by sEH to their corresponding vicinal diols (DiHETEs), which have less biological activity than their precursor metabolites when sensitive endpoints are considered (62).

Linoleic acid metabolites

Another plasma metabolite that dose-dependently and curvilinearly increased with piglet intake of ARA was 12,13-DiHOME, while a nonsignificant trend was observed for 9,10-DiHOME. Linoleic acid epoxidation by CYP results in the 9(10)- and 12(13)-EpOME regioomers, which are rapidly hydrolyzed by sEH in other tissues to their corresponding diols, 9,10- and 12,13-DiHOME (63). Epoxides and diols of linoleic acid produced by activated inflammatory leukocytes have neutrophil chemotactic activity (64). A trend toward increasing plasma linoleic acid with increasing ARA intake was not significant; thus, increased conversion of linoleic acid to 12,13-DiHOME via the CYP/sEH pathway may be regulated by physiological demand due to ARA and not the level of substrate availability.

Eicosapentaenoic acid metabolites

In the current study, dietary DHA significantly increased EPA levels in tissue phospholipids, although this was not reflected in the plasma free fatty acid pool. Dietary DHA also increased the EPA-derived vicinal diol 17,18-DiHETE metabolized in the CYP/sEH pathway, suggesting that DHA retroconversion to EPA may occur to some extent. Due to competitive metabolic effects between n-3 and n-6 fatty acids, the effect of DHA on retroconversion to EPA and subsequent metabolites may be less pronounced when ARA is concomitantly present in the diet, as has been reported for pigs fed both DHA and ARA (65). Although little is known about the role of 17,18-DiHETE, it has been described to have anti-inflammatory properties (66). The EPA-derived COX-2-mediated PGF3α and LOX-5-mediated 5(s)-HEPE appeared unresponsive to dietary DHA changes and may require a stimulus for production.

Docosahexaenoic acid CYP metabolites

The most obvious finding was the dose-responsiveness of plasma 19,20-DiHDPE to dietary DHA intake of the piglets. This is similar to increased plasma 19,20-DiHDPE observed in healthy humans who consumed EPA and DHA from concentrated fish oil (31). However, in the latter study, a much broader range of oxylipins was significantly affected by EPA and DHA than in our study, possibly due to the much larger group sizes used. Little is known about this DHA-derived 19,20-DiHDPE diol, but recent research in sEH knockout mice showed that sEH metabolites, particularly 19,20-DiHDPE, play an important role in normal retinal vascularization (67). To what extent this metabolite is involved in the maturation of the retina remains to be established.
This study investigated the dose responsiveness of different plasma oxylipins to incremental dietary intakes of ARA and DHA in growing piglets. We considered the pig model to be a relatively representative model of the human because the LCPUFA metabolism and enzymes are highly comparable (36, 37, 65). Our data revealed no significant change in circulating COX or LOX products with increasing ARA or DHA in the diet. In general, constitutively expressed COX-1 is the source of prostanoids that serve housekeeping functions, whereas COX-2, induced by inflammatory stimuli and other factors, is the dominant source of prostanoid formation in inflammation (68). Prostanoids produced by COX-1 (e.g., PGE2, TXB2) are responsive to ARA substrate availability (69); however, circulating levels are generally very low to nondetectable unless COX-2 prostanoids are induced by an inflammatory stimulus (48, 68). The profile of prostanoid production is mostly determined by the regulated expression of COX-2 enzymes within cells present at sites of inflammation (68). The thromboids are also generally low in the circulation unless changes in platelet degranulation or blood pressure/volume are induced. In human studies, the LOX-dependent HETEs and CYP-dependent metabolite profiles were generally (but not exclusively) reflective of the parent lipid (i.e., substrate) distribution (19, 58), suggesting that most of the CYP-epoxides accept DHA and ARA as equally efficient substrates (70). Therefore, circulating concentrations of CYP-dependent epoxides and their hydrosylation products appear to be most responsive to changes in dietary PUFA and appear to reflect changes in circulating PUFA concentrations.

In summary, results from the present study demonstrate the dose responsiveness of several circulating vicinal diols to dietary ARA and DHA levels in growing neonatal pigs. These compounds may be markers for active epoxide precursors involved in a variety of homeostatic functions. Dietary ARA levels within physiological ranges did not produce detectable changes in plasma concentrations of eicosanoids synthesized through the LOX- or COX-dependent pathway. Further investigations are warranted to probe the biological implication of dietary modification of these oxylipins as efforts continue to optimize ARA and DHA levels in infant formulas.

REFERENCES

1. Brenna, J. T., B. Varamini, R. G. Jensen, D. A. Diersen-Schade, J. A. Boettcher, and L. M. Arterburn. 2007. Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. Am. J. Clin. Nutr. 85: 1457–1464.
2. Martínez, M. 1992. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 120: S129–S138.
3. Pawlosky, R. J., Y. H. Lin, A. Llanos, P. Menz, R. Uauy, and N. Salem, Jr. 2006. Compartmental analyses of plasma 13C- and 2H-labeled n-6 fatty acids arising from oral administrations of 13C-U-18:2n-6 and 2H5–20:3n-6 in newborn infants. Pediatr. Res. 60: 327–333.
4. Salem, N., Jr., B. Wegher, P. Menz, and R. Uauy. 1996. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc. Natl. Acad. Sci. USA. 93: 49–54.
5. Lin, Y. H., A. Llanos, P. Menz, R. Uauy, N. Salem, Jr., and R. J. Pawlosky. 2010. Compartmental analyses of 2H5-arachidonic acid and C-U-eicosapentaenoic acid toward synthesis of plasma labeled 22:6n-3 in newborn term infants. Am. J. Clin. Nutr. 92: 284–293.
6. Koletzko, B., T. Decsi, and H. Demmelmair. 1996. Arachidonic acid supply and metabolism in human infants born at full term. Lipids. 31: 79–83.
7. O’Connor, D. L., R. Hall, D. Adamkin, N. Assestad, M. Castillo, W. E. Connor, S. L. Connor, K. Fitzgerald, S. Grob-Wargo, E. E. Hartmann, et al. 2001. Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics. 108: 359–371.
8. Westerberg, A. C., R. Schei, C. Henriksen, L. Smith, M. B. Veierod, C. A. Drevon, and P. O. Iversen. 2010. Attention among very low birthweight infants following early supplementation with docosahexaenoic and arachidonic acid. Acta Paediatr. 99: 556–562.
9. Birch, E. E., D. R. Hoffman, Y. S. Castaneda, S. L. Fawcett, D. G. Birch, and R. D. Uauy. 2002. A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. Am. J. Clin. Nutr. 75: 570–580.
10. Birch, E. E., D. R. Hoffman, R. Uauy, and D. G. Birch. 2000. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev. Med. Child Neurol. 42: 174–181.
11. Hoffman, D. R., E. E. Birch, D. G. Birch, R. Uauy, Y. S. Castaneda, M. G. Lapus, and D. H. Wheaton. 2000. Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. J. Pediatr. 136: 540–553.
12. Arterburn, L. M., E. E. Birch, and H. Oken. 2006. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 83: 1467–1470.
13. Abedin, L., E. L. Lien, A. J. Vingrys, and A. J. Sinclair. 1999. The effects of dietary alpha-linolenic acid compared with docosahexaenoic acid on brain, retina, liver, and heart in the guinea pig. Lipids. 34: 475–482.
14. Diau, G. Y., A. T. Hsieh, E. A. Sarkadi-Nagy, W. Vijendran, P. W. Nathanielsz, and J. T. Brena. 2005. The influence of long chain polyunsaturated supplementation on docosahexaenoic acid and arachidonic acid in baboon neonatal central nervous system. BMC Med. 3: 11.
15. Harbige, L. S. 2003. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids. 38: 329–341.
16. Hess, H. A., B. A. Coor, X. Lin, S. K. Jacobii, R. J. Harrell, A. T. Blisklager, and J. Odle. 2008. Enrichment of intestinal mucosal phospholipids with arachidonic and eicosapentaenoic acids fed to suckling piglets is dose and time dependent. J. Nutr. 138: 2164–2171.
17. Tyburczy, C., K. S. Kothapalli, W. J. Park, B. S. Blank, K. L. Bradford, J. P. Zimmer, C. M. Butt, N. Salem, Jr., and J. T. Brena. 2011. Heart arachidonic acid is uniquely sensitive to dietary arachidonic acid and docosahexaenoic acid content in domestic piglets. Prostaglandins Leukot. Essent. Fatty Acids. 85: 355–343.
18. Shearer, G. C., W. S. Harris, T. L. Pedersen, and J. W. Newman. 2010. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 51: 2074–2081.
19. Buczynski, M. W., D. S. Dumlao, and E. A. Dennis. 2009. Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 50: 1015–1038.
20. Stenson, W. F. 2007. Prostaglandins and epithelial response to injury. Curr. Opin. Gastroenterol. 23: 107–110.
21. Wray, J., and D. Bishop-Bailey. 2008. Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp. Physiol. 93: 134–143.
22. Stables, M. J., and D. W. Gilroy. 2011. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 50: 35–51.
23. Serhan, C. N. 2005. Novel eicosanoid and docosanoid mediators: resolvins, docosatetraenes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care. 8: 115–121.
24. Spector, A. A., X. Fang, G. D. Snyder, and N. L. Weintraub. 2004. Epoxyeicosatrienoic acids (ETEs): metabolism and biochemical function. Prog. Lipid Res. 43: 55–90.
25. Strassburg, K. A. M. Huijbregts, K. A. Kortekaas, J. H. Lindeman, T. L. Pedersen, A. Dane, R. Berger, A. Bremkamp, T. Hankemeier, J. van Duynhoven, et al. 2012. Quantitative profiling of oxylipins
through comprehensive LC-MS/MS analysis: application in cardiac surgery. Anal. Bioanal. Chem. 404: 1413–1426.
28. Arita, M., M. Yoshida, S. Hong, E. Tjønna, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005. Resolin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzenesulfonic acid-induced dermal injury. Proc. Natl. Acad. Sci. USA 102: 7671–7676.
29. Ingraham, R. H., R. D. Gless, and H. Y. Lo. 2011. Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions. Curr. Med. Chem. 18: 587–605.
30. Balvers, M. G., K. C. Verhoeckx, S. Bijjima, C. M. Rubingh, J. Meijerink, H. M. Wortelboer, and R. F. Wilkamp. 2012. Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and epoxylin metabolomes in mouse plasma and tissues. Metabolites 2:1130–1147.
31. Keenan, A. H., T. L. Pedersen, K. Fillaus, M. K. Larson, G. C. Ingraham, and R. H. Lo. 2011. Soluble epoxide hydrolase E2 at new glance: novel insights in functional diversity. J. Lipid Res. 53: 1662–1669.
32. Legler, D. F., M. Bruckner, E. Uetz-von Allmen, and P. Krause. 2010. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
33. LIPID MAPS Lipidomics Gateway. 2012. Available at: http://www.lipidmaps.org/
34. Dodds, W. J. 1982. The pig model for biomedical research. Prog. Clin. Biol. Res. 312: 123–380.
35. Miller, E. R., and D. E. Ullrey. 1987. The pig as a model for human studies fed varying ratios of arachidonic acid and DHA. J. Nutr. 117: 767–774.
36. Legler, D. F., M. Bruckner, E. Uetz-von Allmen, and P. Krause. 2010. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
37. LIPID MAPS Lipidomics Gateway. 2012. Available at: http://www.lipidmaps.org/
38. Ingraham, R. H., T. L. Pedersen, K. Fillaus, M. K. Larson, G. C. Ingraham, and R. H. Lo. 2011. Soluble epoxide hydrolase E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
39. Peterson, L. D., N. M. Jeffery, F. Thies, P. Sanderson, E. A. Newsholme, and P. C. Calder. 1998. Eicosapentaenoic and docosahexaenoic acids alter rat spleen leucocyte fatty acid composition and prostaglandin E2 production but have different effects on lymphocyte functions and cell-mediated immunity. Lipids 33: 171–180.
40. Lee, T. H., R. L. Hoover, J. D. Williams, R. I. Sperling, J. Ravalése 3rd, B. W. Spur, D. R. Robinson, E. J. Corey, R. A. Lewis, and K. F. Austen. 1985. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N. Engl. J. Med. 312: 1217–1224.
41. Meydani, S. N., S. Endres, M. M. Woods, B. R. Goldin, C. Soo, A. Mrrill-Labode, C. A. Dinarello, and S. L. Gorban. 1991. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J. Nutr. 121: 547–555.
42. Calcfer, P. C. 2013. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br. J. Clin. Pharmacol. 75: 645–662.
43. Psychogios, N., D. D. Hau, J. Peng, A. C. Guo, R. Mandal, S. Bouatra, I. Sinehnikov, R. Krishnamurthy, R. Eisein, B. Gautham, et al. 2011. The human serum metabolome. PLoS ONE 6: e16957.
44. Fleming, I. 2011. The cytochrome P450 pathway in angiogenesis. Cardiovasc. Drug. Rev. 9: 207–221.
45. Legler, D. F., M. Bruckner, E. Uetz-von Allmen, and P. Krause. 2010. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
46. LIPID MAPS Lipidomics Gateway. 2012. Available at: http://www.lipidmaps.org/
47. Dodds, W. J. 1982. The pig model for biomedical research. Prog. Clin. Biol. Res. 312: 123–380.
48. Miller, E. R., and D. E. Ullrey. 1987. The pig as a model for human studies fed varying ratios of arachidonic acid and DHA. J. Nutr. 117: 767–774.
49. Ingraham, R. H., T. L. Pedersen, K. Fillaus, M. K. Larson, G. C. Ingraham, and R. H. Lo. 2011. Soluble epoxide hydrolase E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
50. Peterson, L. D., N. M. Jeffery, F. Thies, P. Sanderson, E. A. Newsholme, and P. C. Calder. 1998. Eicosapentaenoic and docosahexaenoic acids alter rat spleen leucocyte fatty acid composition and prostaglandin E2 production but have different effects on lymphocyte functions and cell-mediated immunity. Lipids 33: 171–180.
51. Lee, T. H., R. L. Hoover, J. D. Williams, R. I. Sperling, J. Ravalése 3rd, B. W. Spur, D. R. Robinson, E. J. Corey, R. A. Lewis, and K. F. Austen. 1985. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N. Engl. J. Med. 312: 1217–1224.
52. Meydani, S. N., S. Endres, M. M. Woods, B. R. Goldin, C. Soo, A. Mrrill-Labode, C. A. Dinarello, and S. L. Gorban. 1991. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J. Nutr. 121: 547–555.
53. Calcfer, P. C. 2013. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br. J. Clin. Pharmacol. 75: 645–662.
54. Psychogios, N., D. D. Hau, J. Peng, A. C. Guo, R. Mandal, S. Bouatra, I. Sinehnikov, R. Krishnamurthy, R. Eisein, B. Gautham, et al. 2011. The human serum metabolome. PLoS ONE 6: e16957.
55. Fleming, I. 2011. The cytochrome P450 pathway in angiogenesis. Cardiovasc. Drug. Rev. 9: 207–221.
56. Legler, D. F., M. Bruckner, E. Uetz-von Allmen, and P. Krause. 2010. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
57. LIPID MAPS Lipidomics Gateway. 2012. Available at: http://www.lipidmaps.org/
58. Dodds, W. J. 1982. The pig model for biomedical research. Prog. Clin. Biol. Res. 312: 123–380.
59. Miller, E. R., and D. E. Ullrey. 1987. The pig as a model for human studies fed varying ratios of arachidonic acid and DHA. J. Nutr. 117: 767–774.
60. Ingraham, R. H., T. L. Pedersen, K. Fillaus, M. K. Larson, G. C. Ingraham, and R. H. Lo. 2011. Soluble epoxide hydrolase E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 42: 198–201.
61. Meydani, S. N., S. Endres, M. M. Woods, B. R. Goldin, C. Soo, A. Mrrill-Labode, C. A. Dinarello, and S. L. Gorban. 1991. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J. Nutr. 121: 547–555.
62. Calcfer, P. C. 2013. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br. J. Clin. Pharmacol. 75: 645–662.
63. Psychogios, N., D. D. Hau, J. Peng, A. C. Guo, R. Mandal, S. Bouatra, I. Sinehnikov, R. Krishnamurthy, R. Eisein, B. Gautham, et al. 2011. The human serum metabolome. PLoS ONE 6: e16957.